- Home
- REBN vs VRAX Comparison
REBN vs VRAX Comparison
Compare REBN & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- VRAX
- Stock Information
- Founded
- REBN 2015
- VRAX 2013
- Country
- REBN United States
- VRAX United Kingdom
- Employees
- REBN N/A
- VRAX N/A
- Industry
- REBN Restaurants
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- REBN Consumer Discretionary
- VRAX Health Care
- Exchange
- REBN Nasdaq
- VRAX Nasdaq
- Market Cap
- REBN 12.8M
- VRAX 4.7M
- IPO Year
- REBN 2022
- VRAX 2022
- Fundamental
- Price
- REBN $2.75
- VRAX $0.91
- Analyst Decision
- REBN
- VRAX Strong Buy
- Analyst Count
- REBN 0
- VRAX 1
- Target Price
- REBN N/A
- VRAX $3.00
- AVG Volume (30 Days)
- REBN 64.6K
- VRAX 55.7K
- Earning Date
- REBN 08-18-2025
- VRAX 02-05-2025
- Dividend Yield
- REBN N/A
- VRAX N/A
- EPS Growth
- REBN N/A
- VRAX N/A
- EPS
- REBN N/A
- VRAX N/A
- Revenue
- REBN $6,103,732.00
- VRAX $6,331.00
- Revenue This Year
- REBN $335.98
- VRAX $217,274.83
- Revenue Next Year
- REBN N/A
- VRAX N/A
- P/E Ratio
- REBN N/A
- VRAX N/A
- Revenue Growth
- REBN 3.38
- VRAX N/A
- 52 Week Low
- REBN $1.03
- VRAX $0.74
- 52 Week High
- REBN $8.30
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- REBN 57.62
- VRAX 50.78
- Support Level
- REBN $2.61
- VRAX $0.84
- Resistance Level
- REBN $3.16
- VRAX $0.99
- Average True Range (ATR)
- REBN 0.20
- VRAX 0.07
- MACD
- REBN 0.06
- VRAX 0.02
- Stochastic Oscillator
- REBN 68.46
- VRAX 60.20
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.